Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AC Immune (ACIU) Shares Outstanding (Diluted Average): 2014-2017

Historic Shares Outstanding (Diluted Average) for AC Immune (ACIU) over the last 1 years, with Dec 2017 value amounting to $57.9 million.

  • AC Immune's Shares Outstanding (Diluted Average) rose 15.50% to $57.9 million in Q4 2017 from the same period last year, while for Dec 2017 it was $57.9 million, marking a year-over-year increase of 15.50%. This contributed to the annual value of $58.0 million for FY2017, which is 15.77% up from last year.
  • Latest data reveals that AC Immune reported Shares Outstanding (Diluted Average) of $57.9 million as of Q4 2017, which was down 0.08% from $57.9 million recorded in Q2 2017.
  • AC Immune's Shares Outstanding (Diluted Average)'s 5-year high stood at $57.9 million during Q2 2017, with a 5-year trough of $46.0 million in Q4 2015.
  • For the 3-year period, AC Immune's Shares Outstanding (Diluted Average) averaged around $52.0 million, with its median value being $51.1 million (2016).
  • As far as peak fluctuations go, AC Immune's Shares Outstanding (Diluted Average) declined by 2.59% in 2015, and later increased by 15.50% in 2017.
  • Over the past 4 years, AC Immune's Shares Outstanding (Diluted Average) (Quarterly) stood at $47.3 million in 2014, then dropped by 2.59% to $46.0 million in 2015, then grew by 8.80% to $50.1 million in 2016, then rose by 15.50% to $57.9 million in 2017.
  • Its Shares Outstanding (Diluted Average) stands at $57.9 million for Q4 2017, versus $57.9 million for Q2 2017 and $50.1 million for Q4 2016.